Kevin Boyle, Ziopharm Oncology CEO
Ziopharm lays off half its staff after manufacturing issues force delays
New Ziopharm CEO Kevin Boyle has only been at the biotech for less than a month, but he’s already engineering major changes.
Late Monday afternoon …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
